Q1 2023 EPS Estimates for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Increased by Analyst
Q1 2023 EPS Estimates for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Increased by Analyst
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) – Equities research analysts at Capital One Financial lifted their Q1 2023 EPS estimates for Day One Biopharmaceuticals in a report released on Tuesday, March 7th. Capital One Financial analyst N. Quibria now anticipates that the company will earn ($0.58) per share for the quarter, up from their prior estimate of ($0.60). Capital One Financial has a "Overweight" rating and a $40.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals' current full-year earnings is ($2.41) per share. Capital One Financial also issued estimates for Day One Biopharmaceuticals' Q2 2023 earnings at ($0.60) EPS, Q3 2023 earnings at ($0.63) EPS, Q4 2023 earnings at ($0.66) EPS, FY2023 earnings at ($2.47) EPS, Q1 2024 earnings at ($0.50) EPS, Q2 2024 earnings at ($0.52) EPS, Q3 2024 earnings at ($0.56) EPS, Q4 2024 earnings at ($0.59) EPS and FY2024 earnings at ($2.17) EPS.
第一天生物製藥公司（NASDAQ：DAWN — 獲得評級）— 資本一金融的股票研究分析師在 3 月 7 日（星期二）發布的一份報告中提高了他們對第一天生物製藥的 2023 年第一季每股盈利的估計。Capital One 金融分析師基布里亞（N. Quibria）現在預計，該公司將在本季度每股賺取（0.58 美元），高於其先前的估計（0.60 美元）。第一資本金融的股票評級為「超重」評級和 40.00 美元的價格目標。第一天生物製藥當前全年盈利的共識估計為每股（2.41 美元）。資本一財經還發布了第一天生物製藥 2023 年第二季盈利（0.60 美元）盈利，2023 年第三季盈利為每股盈利（0.63 美元），2023 年第四季盈利為每股盈利（0.66 美元），FY2023 盈利為每股盈利（2.47 美元），2024 年第一季盈利為每股盈利（0.50 美元），2024 年第二季盈利（0.52 美元）, 2024 年第四季盈利為每股盈利 (0.59 美元) 及 FY2024 盈利為每股盈利 (2.17 美元)。
A number of other research firms have also weighed in on DAWN. Oppenheimer began coverage on shares of Day One Biopharmaceuticals in a report on Thursday, February 2nd. They issued a "market perform" rating on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $48.00 price objective on shares of Day One Biopharmaceuticals in a report on Tuesday. The Goldman Sachs Group raised their price target on shares of Day One Biopharmaceuticals from $45.00 to $62.00 and gave the company a "buy" rating in a report on Monday, January 9th. HC Wainwright reissued a "buy" rating and issued a $45.00 price target on shares of Day One Biopharmaceuticals in a report on Tuesday. Finally, Piper Sandler raised their price objective on shares of Day One Biopharmaceuticals from $40.00 to $45.00 and gave the company an "overweight" rating in a research report on Sunday, January 8th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $44.14.
許多其他研究公司也在 DAWN 中稱重。奧本海默在 2 月 2 日（星期四）的一份報告中開始對第一天生物製藥的股份進行報導。他們對股票發出了「市場表現」評級。李約翰公司有限責任公司在周二的一份報告中重申了「買入」評級，並對第一天生物製藥的股票發布了 48.00 美元的價格目標。高盛集團將第一天生物製藥股票的價格目標從 $45.00 提高至 62.00 美元，並在 1 月 9 日（星期一）的報告中給予該公司「買入」評級。溫賴特（HC Wainwright）在周二的一份報告中重新發布了「買入」評級，並對第一天生物製藥的股票發布了 45.00 美元的目標價格。最後，派珀·桑德勒提高了他們對第一天生物製藥股票的價格目標從 $40.00 至 $45.00，並在 1 月 8 日星期日的一份研究報告中給該公司一個「超重」評級。一位投資分析師將該股票評級為持有評級，其中七名則為該公司的股票分配了買入評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為「適度買入」，共識目標價為 44.14 美元。
Day One Biopharmaceuticals Price Performance
第一天生物製藥價格表現
DAWN stock opened at $17.95 on Friday. The stock has a market capitalization of $1.32 billion, a PE ratio of -8.27 and a beta of -1.94. The company's 50-day moving average is $20.65 and its 200-day moving average is $20.92. Day One Biopharmaceuticals has a 1 year low of $5.44 and a 1 year high of $28.35.
黎明股票上週五以 17.95 美元開盤。該股的市值為 $1.32 億美元，私募股權比率為 -8.27，測試版為 -1.94。該公司的 50 天移動平均線為 20.65 美元，其 200 天移動平均線為 20.92 美元。第一天生物製藥有 1 年低點的 5.44 美元和 1 年高點 28.35 美元。
Insider Buying and Selling at Day One Biopharmaceuticals
內幕購買和銷售第一天生物製藥
In other news, insider Samuel C. Blackman sold 10,000 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, January 10th. The shares were sold at an average price of $22.86, for a total transaction of $228,600.00. Following the sale, the insider now owns 1,250,148 shares of the company's stock, valued at approximately $28,578,383.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Samuel C. Blackman sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, January 10th. The shares were sold at an average price of $22.86, for a total value of $228,600.00. Following the transaction, the insider now owns 1,250,148 shares in the company, valued at $28,578,383.28. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Julie Papanek Grant sold 25,000 shares of the business's stock in a transaction that occurred on Tuesday, January 3rd. The shares were sold at an average price of $20.65, for a total transaction of $516,250.00. Following the transaction, the director now directly owns 380,000 shares of the company's stock, valued at $7,847,000. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 107,126 shares of company stock worth $2,243,406. 8.70% of the stock is currently owned by company insiders.
在其他消息中，內幕塞繆爾·布萊克曼在 1 月 10 日（星期二）的交易中出售了 10,000 股第一天生物製藥股票。這些股票以 22.86 美元的平均價格出售，總交易額為 228,600.00 美元。出售後，內幕人士現在擁有該公司股票的 1,250,148 股股份，價值約為 28,578,383.28 美元。該銷售在與證券交易委員會的法律文件中披露，該文件可在以下位置獲得 證券交易所網站。在其他消息中，內幕塞繆爾 ·C· 布萊克曼在 1 月 10 日（星期二）發生的交易中出售了 10,000 股公司的股票。這些股票的平均價格為 22.86 美元出售，總價值為 228,600 美元。交易完成後，內幕人士現在擁有該公司的 1,250,148 股股份，價值為 28,578,383.28 美元。銷售在與 SEC 的法律文件中披露，該文件可在以下位置獲得 這個鏈接。此外，董事朱莉·帕帕內克·格蘭特在 1 月 3 日（星期二）發生的交易中出售了 25,000 股該企業的股票。這些股票以 20.65 美元的平均價格出售，總交易額為 516,250.00 美元。交易後，董事現直接擁有該公司股票的 380,000 股股份，價值 7,847,000 美元。可以找到此次銷售的披露 這裡。在過去一個季度，內部人士已經出售了 107,126 股價值 2,243,406 美元的公司股票。8.70％ 的股票目前由公司內部人士擁有。
Hedge Funds Weigh In On Day One Biopharmaceuticals
對沖基金在第一天生物製藥權衡
A number of hedge funds have recently modified their holdings of the company. Alliancebernstein L.P. lifted its position in Day One Biopharmaceuticals by 10.3% during the fourth quarter. Alliancebernstein L.P. now owns 41,900 shares of the company's stock valued at $902,000 after purchasing an additional 3,900 shares during the last quarter. Schonfeld Strategic Advisors LLC raised its holdings in shares of Day One Biopharmaceuticals by 393.9% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 115,500 shares of the company's stock valued at $2,486,000 after purchasing an additional 92,113 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Day One Biopharmaceuticals in the 4th quarter valued at about $663,000. Laurion Capital Management LP raised its holdings in shares of Day One Biopharmaceuticals by 5.4% in the 4th quarter. Laurion Capital Management LP now owns 15,000 shares of the company's stock valued at $323,000 after purchasing an additional 763 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Day One Biopharmaceuticals in the 4th quarter valued at about $2,324,000. 86.08% of the stock is currently owned by institutional investors.
一些對沖基金最近修改了他們對該公司的持有量。在第四季度，聯博 L.P. 在第一天生物製藥的地位提升了 10.3%。聯博在上一季度額外購買 3,900 股股份後，現在擁有該公司 41,900 股股份，價值為 902,000 美元。申菲爾德戰略顧問有限責任公司在第四季度將其在第一天生物製藥股份的持有量提高了 393.9％。尚菲爾德策略顧問有限責任公司現在擁有該公司的 115,500 股股票，價值為 2,486,000 美元，在上個季度額外購買 92,113 股股票後。Squarepoint 行動有限責任公司在第四季度購買了第一天生物製藥股份的新股份，價值約為 663,000 美元。勞永資本管理有限公司在第一季度提高了其在第一天生物製藥股份的持有量 5.4％。勞永資本管理有限公司在上個季度額外購買 763 股股票後，擁有該公司 15,000 股價值 323,000 美元的股票。最後，挪威銀行在第四季度購買了第一天生物製藥股份的新股份，價值約為 2,324,000 美元。86.08％ 的股票目前由機構投資者擁有。
Day One Biopharmaceuticals Company Profile
第一天生物製藥公司簡介
(Get Rating)
(取得評分)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.
Day One 生物製藥公司是臨床階段的生物製藥公司，為患有基因定義癌症的患者開發和商業化靶向療法。其主要候選產品是 DAY101，這是一種口服腦滲透劑 II 型泛快速加速纖維肉瘤激酶抑製劑，正在用於復發/漸進性低度膠質瘤兒童患者的 II 期臨床試驗中。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Day One Biopharmaceuticals (DAWN)
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
- How to Buy High Yielding Dividend Stocks
- Oracle Has Spoken: Shares Fall 5%
- 獲得第一天生物製藥（黎明）的 Stocknews.com 研究報告的免費副本
- 2 海上鑽探股票將提取巨額利潤
- 前面有兩位數字的三個主要股票
- 投資者可以信任消費者提升美國戶外品牌嗎？
- 如何購買高收益股息股票
- 甲骨文已經說話:股價下跌 5%
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收第一天生物製藥的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關第一天生物製藥及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。